hey mate yeah I rarely post on IMM as they are just chugging...

hey mate yeah I rarely post on IMM as they are just chugging along, when it’s catalyst based investing everything between those catalysts is just white noise. Day to day trading doesn’t phase me one bit. Agreed that If trials with Opdivo do commence this creates competition between big pharma and that’s what we want.

A licensing agreement is very possible too, but I think management might take the approach of Viralytics and sell the lot and move on to the next venture, much like what Malcolm McColl has done - he has founded a company called ImmVirx (I think that’s the name, if it isn’t it’s very close to it). But as long IMM don’t accept a a lowball offer like VLA did it’s happy times.

The most logical acquisition would be a back ended deal contingent upon Efti getting approval for various indications.

Ideally we get to a market cap of $1.5bn organically and at that price an acquisition of $2bn upfront with another $2bn on the back end doesn’t seem so outrageous.